|
99
|
349
|
3c9wA |
Crystal structure of erk-2 with hypothemycin covalently bound |
|
99
|
356
|
3cgfA |
Irak-4 inhibitors (part ii)- a structure based assessment of imidazo[1,2 a]pyridine binding |
|
103
|
348
|
3bx5A |
P38 alpha map kinase complexed with bms-640994 |
|
102
|
347
|
3bv2A |
Morpholino pyrrolotriazine p38 alpha map kinase inhibitor compound 30 |
|
101
|
348
|
3bv3A |
Morpholino pyrrolotriazine p38 alpha map kinase inhibitor compound 2 |
|
112
|
352
|
2zoqA |
Structural dissection of human mitogen-activated kinase erk1 |
|
113
|
349
|
2zb1A |
Crystal structure of p38 in complex with biphenyl amide inhibitor |
|
107
|
356
|
2zdtA |
Crystal structure of human jnk3 complexed with an isoquinolone inhibitor |
|
111
|
349
|
2zb0A |
Crystal structure of p38 in complex with biphenyl amide inhibitor |
|
103
|
355
|
2zduA |
Crystal structure of human jnk3 complexed with an isoquinolone inhibitor |
|
103
|
340
|
2z7lA |
Unphosphorylated mitogen activated protein kinase erk2 in complex with (4-{[5-carbamoyl-4-(3-methylanilino)pyrimidin 2-yl]amino}phenyl)acetic acid |
|
107
|
349
|
2zazA |
Crystal structure of p38 in complex with 4-anilino quinoline inhibitor |
|
105
|
348
|
2yiwA |
Triazolopyridine inhibitors of p38 kinase |
|
113
|
351
|
2yixA |
Triazolopyridine inhibitors of p38 |
|
108
|
348
|
2yisA |
Triazolopyridine inhibitors of p38 kinase. |
|
120
|
350
|
2y9qA |
Crystal structure of human erk2 complexed with a mapk docking peptide |
|
102
|
360
|
2xs0A |
Linear binding motifs for jnk and for calcineurin antagonistically control the nuclear shuttling of nfat4 |
|
108
|
350
|
2y8oA |
Crystal structure of human p38alpha complexed with a mapk docking peptide |
|
116
|
365
|
2xrwA |
Linear binding motifs for jnk and for calcineurin antagonistically control the nuclear shuttling of nfat4 |
|
110
|
355
|
2wajA |
Crystal structure of human jnk3 complexed with a 1-aryl-3,4- dihydroisoquinoline inhibitor |
|
96
|
356
|
2r9sA |
C-jun n-terminal kinase 3 with 3,5-disubstituted quinoline inhibitor |
|
104
|
348
|
2rg5A |
Phenylalanine pyrrolotriazine p38 alpha map kinase inhibitor compound 11b |
|
110
|
349
|
2rg6A |
Phenylalanine pyrrolotriazine p38 alpha map kinase inhibitor compound 11j |
|
108
|
348
|
2qd9A |
P38 alpha map kinase inhibitor based on heterobicyclic scaffolds |
|
101
|
348
|
2puuA |
Crystal structure of p38 complex with 1-(5-tert-butyl-2-p-tolyl-2h-pyrazol-3-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)naphthalen-1-yl]urea |
|
85
|
348
|
2ozaB |
Structure of p38alpha complex |
|
101
|
356
|
2p33A |
Synthesis and sar of aminopyrimidines as novel c-jun n-terminal kinase (jnk) inhibitors |
|
104
|
349
|
2okrA |
Crystal structure of the p38a-mapkap kinase 2 heterodimer |
|
105
|
344
|
2ojiA |
Crystal structure of erk2 in complex with n-benzyl-4-(4-(3-chlorophenyl)-1h-pyrazol-3-yl)-1h-pyrrole-2-carboxamide |
|
111
|
344
|
2ojjA |
Crystal structure of erk2 in complex with (s)-n-(1-(3-chloro-4-fluorophenyl)-2-hydroxyethyl)-4-(4-(3-chlorophenyl)-1h-pyrazol-3-yl)-1h-pyrrole-2-carboxamide |
|
105
|
355
|
2o2uA |
Crystal structure of human jnk3 complexed with n-(3-cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)-2-fluorobenzamide |
|
99
|
355
|
2ok1A |
Crystal structure of jnk3 bound to n-benzyl-4-(4-(3-chlorophenyl)-1h-pyrazol-3-yl)-1h-pyrrole-2-carboxamide |
|
99
|
349
|
2onlA |
Crystal structure of the p38a-mapkap kinase 2 heterodimer |
|
104
|
339
|
2ojgA |
Crystal structure of erk2 in complex with n,n-dimethyl-4-(4-phenyl-1h-pyrazol-3-yl)-1h-pyrrole-2-carboxamide |
|
95
|
355
|
2o0uA |
Crystal structure of human jnk3 complexed with n-{3-cyano-6-[3-(1-piperidinyl)propanoyl]-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-2-yl}-1-naphthalenecarboxamide |
|
109
|
359
|
2lgcA |
Joint nmr and x-ray refinement reveals the structure of a novel dibenzo[a,d]cycloheptenone inhibitor/p38 map kinase complex in solution |
|
108
|
348
|
2npqA |
A novel lipid binding site in the p38 alpha map kinase |
|
96
|
357
|
2no3A |
Novel 4-anilinopyrimidines as potent jnk1 inhibitors |
|
115
|
349
|
2i0hA |
The structure of p38alpha in complex with an arylpyridazinone |
|
79
|
309
|
2i6lA |
Crystal structure of human mitogen activated protein kinase 6 (mapk6) |
|
95
|
358
|
2h96A |
Discovery of potent, highly selective, and orally bioavailable pyridine carboxamide c-jun nh2-terminal kinase inhibitors |
|
105
|
348
|
2gtnA |
Mutated map kinase p38 (mus musculus) in complex with inhbitor pg-951717 |
|
101
|
348
|
2ghlA |
Mutant mus musculus p38 kinase domain in complex with inhibitor pg-874743 |
|
107
|
345
|
2gphA |
Docking motif interactions in the map kinase erk2 |
|
107
|
348
|
2gtmA |
Mutated mouse p38 map kinase domain in complex with inhibitor pg-892579 |
|
77
|
357
|
2gmxA |
Selective aminopyridine-based c-jun n-terminal kinase inhibitors with cellular activity |
|
96
|
348
|
2ghmA |
Mutated map kinase p38 (mus musculus) in complex with inhbitor pg-895449 |
|
88
|
349
|
2fysA |
Crystal structure of erk2 complex with kim peptide derived from mkp3 |
|
111
|
348
|
2gfsA |
P38 kinase crystal structure in complex with ro3201195 |
|
73
|
355
|
2g01A |
Pyrazoloquinolones as novel, selective jnk1 inhibitors |
